NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients

CompletedN/A

Sponsor: Myung-Ju Ahn

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Immunnotherapy group

Countries: South Korea

The pragmatic clinical trial to elucidate optimal target population of immunotherapy from real-world lung cancer patients

Eligibility overview

Sex: ALL

Age: 19 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

7-1 Inclusion criteria 7-1-1 Immunotherapy arm (prospective data collection)

* Male and female patients aged 19 years and above
* Patients with histologically confirmed NSCLC
* Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
* Patients receiving reimbursed immunotherapy as second-line therapy (in case of targeted therapy, patients receiving immunotherapy after targeted therapy-platinum-based chemotherapy) or as reimbursed first-line therapy
* Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties) 7-1-2 Cytotoxic chemotherapy arm (prospective/retrospective data collection)
* Male and female patients aged 19 years and above
* Patients with histologically confirmed NSCLC
* Patients on palliative therapy for recurrence after surgery or de novo advanced and metastatic disease
* Prospective: Patients receiving reimbursed cytotoxic chemotherapy as second-line therapy after failure of platinum-based chemotherapy
* Retrospective: In addition to the prospective data, retrospective data will be collected from medical records of 680 patients (or more) who had records of receiving cytotoxic chemotherapy between January 1, 2017, and December 31, 2018 (1:1 comparison between the immunotherapy arm and the chemotherapy arm). If the patient did not die within the first 12 months after diagnosis, available follow-up data of at least 12 months will be collected from the medical records of the participating institution.Patients who provided written informed consent for the study (including the secondary use of the study data and sharing with third parties) 7-2 Exclusion criteria 7-2-1 Immunochemotherapy arm
* Patients receiving immunotherapy without reimbursement
* Patients who do not provide consent to the study 7-2-2 Cytotoxic chemotherapy arm
* Patients receiving cytotoxic chemotherapy without reimbursement
* Patients who do not provide consent to the study

Locations (1)

Seoul, South Korea